Yasui, Hiroshi <br/><br/>
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.  [electronic resource] 

 -  Blood  Jul 2005 
 - 706-12 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0006-4971 
<br/><br/><label>Standard No.: </label>10.1182/blood-2005-02-0838  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--administration & dosage<br/>Apoptosis--drug effects<br/>Bone Marrow Cells--drug effects<br/>Caspases--metabolism<br/>Cell Adhesion--drug effects<br/>Cell Line, Tumor<br/>Cyclin D1--metabolism<br/>Dexamethasone--administration & dosage<br/>Drug Resistance, Neoplasm<br/>Drug Synergism<br/>Etodolac--administration & dosage<br/>Humans<br/>Insulin-Like Growth Factor I--pharmacology<br/>Interleukin-6--pharmacology<br/>Multiple Myeloma--drug therapy<br/>Myeloid Cell Leukemia Sequence 1 Protein<br/>Neoplasm Proteins--metabolism<br/>Poly(ADP-ribose) Polymerases--metabolism<br/>Proto-Oncogene Proteins c-bcl-2--metabolism<br/>Stereoisomerism